Discovery of novel mifepristone derivatives via suppressing KLF5 expression for the treatment of triple-negative breast cancer.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  European journal of medicinal chemistry

• Publication date

  2018-02-25

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.ejmech.2018.01.056PMID 29407962
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• miR-217 inhibits triple-negative breast cancer cell growth, migration, and invasion through targeting KLF5

  2017cited by this paper
• Acetic Acid Accelerated Visible-Light Photoredox Catalyzed N-Demethylation of N,N-Dimethylaminophenyl Derivatives

  2017cited by this paper
• Ursolic acid derivative FZU-03,010 inhibits STAT3 and induces cell cycle arrest and apoptosis in renal and breast cancer cells

  2017cited by this paper
• Synthesis of metapristone through an efficient N-demethylation of mifepristone

  2016cited by this paper
• Scaffold Repurposing of Old Drugs Towards New Cancer Drug Discovery.

  2016cited by this paper
• Mifepristone Suppresses Basal Triple-Negative Breast Cancer Stem Cells by Down-regulating KLF5 Expression

  2016cited by this paper
• Chitosan-based nanoparticles for improved anticancer efficacy and bioavailability of mifepristone

  2016cited by this paper
• Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

  2016cited by this paper
• Evolutions in fragment-based drug design: the deconstruction-reconstruction approach.

  2015cited by this paper
• The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27Kip1

  2015cited by this paper
• Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease.

  2015cited by this paper
• Ataxin-3 like (ATXN3L), a member of the Josephin family of deubiquitinating enzymes, promotes breast cancer proliferation by deubiquitinating Krüppel-like factor 5 (KLF5)

  2015cited by this paper
• BAP1 promotes breast cancer cell proliferation and metastasis by deubiquitinating KLF5

  2015cited by this paper
• Advances in small-molecule drug discovery for triple-negative breast cancer.

  2015cited by this paper
• Therapeutic targets of triple‐negative breast cancer: a review

  2015cited by this paper
• Selective, nontoxic CB(2) cannabinoid o-quinone with in vivo activity against triple-negative breast cancer.

  2015cited by this paper
• Triple negative breast cancer: looking for the missing link between biology and treatments

  2015cited by this paper
• Response and resistance to BET bromodomain inhibitors in triple negative breast cancer

  2015cited by this paper
• Targeting Krüppel-like factor 5 (KLF5) for cancer therapy.

  2015cited by this paper
• A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.

  2015cited by this paper
• Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study.

  2014cited by this paper
• WWOX suppresses KLF5 expression and breast cancer cell growth.

  2014cited by this paper
• Krüppel-like factors in cancer progression: three fingers on the steering wheel

  2013cited by this paper
• Krüppel-like factors in cancer

  2013cited by this paper
• Krüppel-like Factor 5 Transcription Factor Promotes Microsomal Prostaglandin E2 Synthase 1 Gene Transcription in Breast Cancer*

  2013cited by this paper
• Role of KLF5 in hormonal signaling and breast cancer development.

  2013cited by this paper
• TAZ antagonizes the WWP1-mediated KLF5 degradation and promotes breast cell proliferation and tumorigenesis.

  2012cited by this paper
• Dissecting the heterogeneity of triple-negative breast cancer.

  2012cited by this paper
• YAP promotes breast cell proliferation and survival partially through stabilizing the KLF5 transcription factor.

  2012cited by this paper
• The induction of KLF5 transcription factor by progesterone contributes to progesterone-induced breast cancer cell proliferation and dedifferentiation.

  2011cited by this paper
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011cited by this paper
• Triple-negative breast cancer.

  2010cited by this paper
• Mammalian Krüppel-like factors in health and diseases.

  2010cited by this paper
• Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study.

  2009cited by this paper
• KLF5 Promotes Breast Cell Survival Partially through Fibroblast Growth Factor-binding Protein 1-pERK-mediated Dual Specificity MKP-1 Protein Phosphorylation and Stabilization*

  2009cited by this paper
• Essential role of KLF5 transcription factor in cell proliferation and differentiation and its implications for human diseases

  2009cited by this paper
• Triple-negative breast cancer: therapeutic options.

  2007cited by this paper
• Expression of KLF5 is a Prognostic Factor for Disease-Free Survival and Overall Survival in Patients with Breast Cancer

  2006cited by this paper
• Clinical Pharmacokinetics of Mifepristone

  1997cited by this paper
• Pharmacokinetic study of RU 486 and its metabolites after oral administration of single doses to pregnant and non-pregnant women.

  1993cited by this paper
• Distribution of RU 486 and its demethylated metabolites in humans.

  1989cited by this paper
• Pharmacokinetics of the antiprogesterone RU 486 in women during multiple dose administration.

  1989cited by this paper
• Levels of the antiprogestin RU 486 and its metabolites in human blood and follicular fluid following oral administration of a single dose.

  1989cited by this paper
• Pharmacokinetics and metabolism of RU 486.

  1987cited by this paper
• Molecular genetics of Krüppel, a gene required for segmentation of the Drosophila embryo

  1985cited by this paper

• Targeting glucocorticoid receptor to enhance immunotherapy response in triple negative breast cancer

  2026cites this paper
• Synthesis and biological evaluation of chromone derivatives against triple-negative breast cancer cells

  2023cites this paper
• Targeting Breast Cancer Stem Cells

  2023cites this paper
• Histone Deacetylase Inhibitors (HDACi) Promote KLF5 Ubiquitination and Degradation in Basal-like Breast Cancer

  2022cites this paper
• Transcriptional Factor KLF11 is a new prognostic biomarker and potential therapeutic target in human sporadic invasive breast cancer

  2022cites this paper
• Targeting key proteins involved in transcriptional regulation for cancer therapy: Current strategies and future prospective

  2022cites this paper
• Synthesis and evaluation of novel thiosemicarbazone and semicarbazone analogs with both anti-proliferative and anti-metastatic activities against triple negative breast cancer.

  2021cites this paper
• Rational design and synthesis of 6-aryl-6H-benzo[c]chromenes as non-steroidal progesterone receptor antagonists for use against cancers.

  2021cites this paper
• The roles and regulation of the KLF5 transcription factor in cancers

  2021cites this paper
• Recent progress in small molecule agents for the targeted therapy of triple-negative breast cancer.

  2020cites this paper
• Krüppel-like factors in breast cancer: Function, regulation and clinical relevance.

  2019cites this paper
• CDX1/2 and KLF5 Expression and Epigenetic Modulation of Sonic Hedgehog Signaling in Gastric Adenocarcinoma

  2019cites this paper
• Clinical Significance of Lysophosphatidic Acid Receptor-2 (LPA2) and Krüppel-Like Factor 5 (KLF5) Protein Expression Detected by Tissue Microarray in Gastric Adenocarcinoma

  2019cites this paper
• Effective enmein-type mimics of clinical candidate HAO472: Design, synthesis and biological evaluation.

  2019cites this paper
• Biomimetic Oxidative Coupling Cyclization Enabling Rapid Construction of Isochromanoindolenines.

  2018cites this paper
• Palladium nanodendrites uniformly deposited on the surface of polymers as an efficient and recyclable catalyst for direct drug modification via Z-selective semihydrogenation of alkynes

  2018cites this paper